

February 4, 2016

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code: 531099

Sub: Outcome of Board Meeting

Re: Financial Results for the Quarter and nine months period ended December 31, 2015

Dear Sir(s),


With reference to the captioned subject, please find enclosed herewith, the Financial Results of the Company for the Quarter and Nine Months Ended December 31, 2015 which was approved by the Board of Directors in their meeting held today i.e. February 4, 2016

Also attach is Limited Review Report for the period ended on December 31, 2015 given by the Statutory Auditor of the Company.

You are requested to take note of the same.

Thanking You,

Yours faithfully
For **Rubra Medicaments Limited**



Mayuresh Tawde
Director
DIN – 01999743

RUBRA MEDICAMENTS LIMITED

Part I (Rupees in Lacs)							
Statement of Standalone Unaudited Results for the Quarter and 9 months period ended 31/12/2015							
Sr. No	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for pervious period ended	Previous year Ended
		31/12/2015	30/09/2015	31/12/2014	31/12/2015	31/12/2014	31/03/2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from operations						
	Net Sales/Income form Operations (Net of Excise Duty)	6.47	6.12	0.00	12.59	0.00	0.00
	Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income from Operations (Net)	6.47	6.12	0.00	12.59	0.00	0.00
2	Expenses						
a	Cost of Materials Consumed	0.00	0.00	0.00	0.00	0.00	0.00
b	Purchases of Stock-in-trade	5.08	2.06	0.00	7.14	0.00	0.00
c	Changes in Inventories of fininshed goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
d	Employee Benefit Expense	0.45	0.45	0.00	0.90	0.00	0.42
e	Depreciation and amortisation expenses	0.00	0.00	0.00	0.00	0.00	0.00
f	Other Expenses (Any item exceeding 10% of the total expenses relating to continuing operatons to be shown separately)	0.69	3.44	1.61	4.13	5.54	7.06
	Total Expenses	6.22	5.95	1.61	12.17	5.54	7.48
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	0.25	0.17	-1.61	0.42	-5.54	-7.48
4	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) from Ordinary activities before finance costs and exceptional items (3+4)	0.25	0.17	-1.61	0.42	-5.54	-7.48
6	Finance Cost	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit / (Loss) from Ordinary activities after finance costs but before exceptional items (5+6)	0.25	0.17	-1.61	0.42	-5.54	-7.48
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary activities before tax (7+8)	0.25	0.17	-1.61	0.42	-5.54	-7.48
10	Tax Expenses	0.00	0.00	0.00	0.00	0.00	0.00
11	Profit / (Loss) from Ordinary activities after tax (9+10)	0.25	0.17	-1.61	0.42	-5.54	-7.48
12	Extraordinary Items (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11+12)	0.25	0.17	-1.61	0.42	-5.54	-7.48
14	Share of Profit/(Loss) of associates	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
16	Net Profit / (Loss) after taxes, minority interest and share of profit /(loss) of associates (13+14+15)	0.25	0.17	-1.61	0.42	-5.54	-7.48
17	Paid-up equity share capital (Face value of the Share is Rs.10/- each)	546.83	546.83	546.83	546.83	546.83	546.83
18	Reserves excluding Revaluation Reserves as per balance sheet) of previous accounting year						-507.75
19.i	Earnings Per Share (EPS) (before Extraordinary items) of Rs. 10/- each (not to be annualized)						
	a) Basic	0.00	0.00	-0.03	0.01	-0.10	-0.14
	b) Diluted	0.00	0.00	-0.03	0.01	-0.10	-0.14
19.ii	Earnings Per Share (EPS) (after Extraordinary items) of Rs. 10/- (not to be annualized)						
	a) Basic	0.00	0.00	-0.03	0.01	-0.10	-0.14
	b) Diluted	0.00	0.00	-0.03	0.01	-0.10	-0.14
Notes:							
1	The above results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today						
2	The Segment-wise details are not applicable to the company as company has no segments.						
3	The result is provisional and unaudited and subject to change, regrouping and restatement.						

Date: February 4, 2016
Place: Mumbai

For Rubra Medicaments Limited


Managing Director



Limited Review Report of the Auditors

To,
The Board of Directors
Rubra Medicaments Limited
Hyderabad

Sub: Limited Review Report

We have reviewed the accompanying statement of unaudited financial results of Rubra Medicaments Limited for the period ended December 31, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Prakash Modi & Associates
Chartered Accountants
FRN: 116900W

Prakash Modi

Prakash Modi
Partner
M No: 101463



Place: Mumbai

Dated: 4th February 2016